Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 9, 2003, Pages 1266-1278

  Dominiczak, Marek H ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Metabolic syndrome; Obesity; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FIBRIC ACID DERIVATIVE; GLICLAZIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; REACTIVE OXYGEN METABOLITE; THIAZIDE DIURETIC AGENT; VITAMIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL METABOLISM; CLINICAL LABORATORY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIETARY INTAKE; DYSLIPIDEMIA; ENDOCRINE FUNCTION; EPIDEMIC; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; LIPID TRANSPORT; METABOLITE; MICROALBUMINURIA; OBESITY; OXIDATIVE STRESS; PATIENT MONITORING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOXICITY;

CARDIOVASCULAR DISEASES; CLINICAL LABORATORY TECHNIQUES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; INSULIN; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 0142093106     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.194     Document Type: Review

References (133)

1. Diamond J. The double puzzle of diabetes. Nature 2003; 423:599-602.
2. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414:788-91.
3. Mooradian A. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 2003; 163:33-40.
4. Savage PJ. Cardiovascular complications of diabetes mellitus. Ann Intern Med 1996; 124:123-6.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
6. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
7. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes and cardiovascular risk in children: an American Heart Association Scientific Statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003; 107:1448-53.
8. Kind H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
9. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-77.
10. Campbell I. The obesity epidemic: can we turn the tide? Heart 2003; 89 (Suppl II):ii22-4.
11. Gloyn AL, McCarthy MI. The genetics of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2001;15:298-308.
12. Kobberling J, Tillil H. Empirical risk figures for first-degree relatives of non-insulin dependent diabetics. In: Kobberling J, Tattersall R, editors. The genetics of diabetes mellitus. London: Academic Press, 1982:201-9.
13. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26:163-75.
14. Semenkovich CF, Heinecke JW. The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 1997; 46: 327-34.
15. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-81.
16. Vollenveider P. Insulin resistant states and insulin signaling. Clin Chem Lab Med 2003; 41:1107-19.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26:S4-S20.
18. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968-77.
19. Must A, Spadano J, Coakley EH, Field AE, Coldiz G, Dietz WH. The disease burden associated with overweight and obesity. J Am Med Assoc 1999; 282:1523-29.
20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285:2486-97.
22. Dominiczak MH. Metabolic syndrome. Curr Opin Lipidol 2003; 14:329-32.
23. Meigs JB. The metabolic syndrome. Br Med J 2003; 327:61-2.
24. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75:809-17.
25. Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol 1990; 15:S18-S25.
26. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002; 51:3120-7.
27. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26(Suppl 1) S80-S82. (ADA).
28. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in diabetic subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
29. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Br Med J 2002; 324:939-42.
30. Stern MP. Diabetes and cardiovascular disease: the 'common soil' hypothesis. Diabetes 1995; 44:369-74.
31. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1:57-9.
32. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41:1120-30.
33. Mann JI. Diet and risk of coronary heart disease and type 2 diabetes. Lancet 2002; 306:783-9.
34. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Illanne-Parikka P, et al Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects wit impaired glucose tolerance. N Engl J Med 2001; 344:1343-50.
35. Dominiczak MH. Glucose homeostasis and fuel metabolism. In: Baynes J, Dominiczak MH, editors. Medical bio-chemistry. London: Mosby, 1999:243-66.
36. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995; 44:863-70.
37. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53:319-36.
38. McGarry D. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51:7-18.
39. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clinic Proceedings 2003; 78:447-56.
40. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40:405-12.
41. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1996; 46:223-34.
42. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999:48:1-9.
43. Miyata T, Ishikawa T, van Ypersele de Strihou C. Carbonyl stress and diabetic complications. Clin Chem Lab Med 2003; 41:1150-8.
44. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-20.
45. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin Chem Lab Med 2003; 41:1144-9.
46. Wolff SP, Dean RT. Glucose autooxidation and protein modification: the potential role of 'autooxidative glycosylation' in diabetes mellitus. Biochem J 1987; 245:243-50.
47. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
48. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
49. Gersony RD, Fuster V. Atherogenesis. In: Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing, 2nd ed. Washington DC: AACC Press, 2000:31-46.
50. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-6.
51. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
52. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003; 52:1-8.
53. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341:240-6.
54. Mora S, Pessin JE. An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 2002; 18:345-56.
55. Straub S, Sharp GWG. Glucose-stimulated signaling pathways in biphasic insulin secretion. Diabetes Metab Res Rev 2002; 18:451-63.
56. Hermann C, Assmus B, Urbich C, Zeilher AM, Dimmeler S. Insulin-mediated stimulaton of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Atheroscler Thromb Vasc Biol 2000; 20:402-16.
57. Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA 1996; 93:6231-5.
58. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52:239-43.
59. Zhang H, Kumar S, Barnett A, Eggo M. Tumour necrosis factor-alpha exerts dual effects on human adipose leptin synthesis and release. Mol Cell Endocrinol 2000; 159: 79-88
60. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377:527-9.
61. Hardie L, Guilhot N, Trayhurn P. Regulation of leptin production in cultured mature white adipocytes. Horm Metab Res 1996; 28:685-9.
62. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360:57-8.
63. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271:665-8.
64. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995; 44:1239-42.
65. Marcucci M, Griffin M, Estrada P, Barucci N, Cline G, Shulman G. Elevations in free fatty acids induce insulin resistance via inhibition of IRS- 1 -associated PI-3-kinase activity in vivo. Diabetes 1998; 4 (Suppl):284A.
66. Pan DA, Lillioja S, Kriketos AD Milner MR Baur LA, Bogardus C, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46:983-8.
67. Laakso M, Barrett-Connor E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 1989; 9:665-72.
68. Garg A, Helderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metabolism 1988; 37:982-7.
69. Dominiczak MH. Apolipoproteins and lipoproteins in human plasma. In: Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing, 2nd ed. Washington DC: AACC Press, 2000:1-30.
70. Dominiczak MH. Hyperlipidaemia and cardiovascular disease. Curr Opin Lipidol 2002; 13:343-5.
71. Dominiczak MH. Risk factors for coronary disease: the time for a paradigm shift? Clin Chem Lab Med 2001: 39:907-19.
72. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994; 14:1767-74.
73. Austin MA, King MD, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
74. Leary ET, Wang T, Baker DJ, Cilla D, Zhong J, Warnick GR, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 1998; 44:2490-8.
75. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19:2474-86.
76. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterisation of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267:14987-97.
77. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240:1546-8.
78. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1:447-56.
79. Schmidt AM, Hori O, Chen Jing X, Li J F, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96:1395-403.
80. Dominiczak MH. Atherosclerosis. In: Colaco CALS, editor. The glycation hypothesis of atherosclerosis. Austin, TX: Landes Bioscience, 1997:1-28.
81. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143:1649-56.
82. Bucciarelli LG, Wendt T, Qu Wu, Lu Yan, Lalla E, Rong Ling Ling, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 16:2827-35.
83. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-55.
84. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50:2792-808.
85. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99:15598-601.
86. Du X, Matsumura T, Szabo C, Edelstein D, Brownlee M. Hyperglycemia-induced superoxide activates PKC, the hexosamine pathway, AGE formation, and NFκB via poly (ADP-ribose) polymerase inhibition of GAPDH. Diabetes 2002; 51(Suppl 2):A175.
87. Schiekofer S, Andrassy M, Chen J, Rudofsky R, Schneider J, Wendt T, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK and nuclear factor kappaB in PBMCs. Diabetes 2003; 52:621-33.
88. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404:787-90.
89. Korshunov SS, Skulachev VP, Starkov AA. High protein potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 1997; 416: 15-8.
90. Roitt I, Brostoff J, Male D. Immunology. London: Mosby, 1998:1-11.
91. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Eng J Med 1997; 336:1066-71.
92. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-7.
93. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972-8.
94. Ford ES. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 1999; 22:1971-7.
95. Kern PA, Ranganathan S, Li Chung-Ling, Ranganathan G. Adipose TNF and IL-6 expression in human obesity-associated insulin resistance. Diabetes 2000; 49(Supp.1):A24.
96. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596-600.
97. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001; 286:327-34.
98. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999; 353:1649-52.
99. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. J Am Med Assoc 2000; 283:221-8.
100. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51:1131-7.
101. Whicher J, Biasucci L, Rifai N. Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 1999; 37:495-503.
102. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among healthy women. Circulation 1998; 98:731-3.
103. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43.
104. Liebl A. Challenges in optimal metabolic control of diabetes. Diabetes Metab Res Rev 2002; 18:S36-S41.
105. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
106. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
107. 1c - a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003; 41:1182-90.
108. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321:405-12.
109. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Intensive therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348:2294-303.
110. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. J Am Med Assoc 2003; 289:2560-72.
111. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Mad J 1998; 317:703-12.
112. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeiersson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-20.
113. Battisti WP, Palmisano J, Keane WF. Dyslipidemia in patients with type 2 diabetes. The relationship of lipids, kidney disease, and cardiovascular disease. Clin Chem Lab Med 2003; 41:1174-81.
114. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-93.
115. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, MCDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2003; 25:750-86.
116. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, MCDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48:436-72.
117. Kernohan AFB, Perry CG, Small M..Clinical impact of the new criteria for the diagnosis of diabetes mellitus. Clin Chem Lab Med 2003; 41:1239-45.
118. Jørgensen LGM, Brandslund I, Petersen PH, de Fine Olivarius N, Stahl M. The effect of the new ADA and WHO guidelines on the number of diagnosed cases of diabetes mellitus. Clin Chem Lab Med 2003; 41:1246-50.
119. Little RR. Glycated hemoglobin standardization-National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med 2003; 41:1291-8.
120. 1c: analysis and standardization. Clin Chem Lab Med 2003; 41:1259-65.
121. Price CP. Point-of-care testing in diabetes mellitus. Clin Chem Lab Med 2003; 41:1213-9.
122. Mastrototaro J. The MiniMed continuous glucose monitoring system (CGMS). J Pediatr Endocrinol Metab 1999; 12 (Suppl 3):S751-8.
123. Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase HP. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 1999; 22:1708-14.
124. Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41:745-59.
125. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16:996-1003.
126. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Mad 1999; 130:933-7.
127. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131:376-86.
128. Yarnell JW, Baker IA Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83:836-44.
129. Stec JJ, Silbershatz H, Toiler GH, Matheney TH, Sutherland P, Lipinska I, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease the Framingham Offspring Population. Circulation 2000; 102:1634-8.
130. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998; 21:841-8.
131. Stehouwer CDA. Heterogeneity of the asssociation between plasma homocysteine and atherothrombotic disease: insights from studies of vascular structure and function. Clin Chem Lab Med 2001; 39:705-9.
132. Yeromenko Y, Lavie L, Levy Y. Homocysteine and cardiovascular risk in patients with diabetes mellitus. Nutr Metab Cardiovasc Dis 2001; 11:108-16.
133. Pearson TA, Mensah,GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association [AHA/CDC Scientific Statement]. Circulation 2003; 107:499-511.